Market Newsdesk

Elastic Announces Elasticsearch Logsdb Index Mode to Reduce Log Data Storage Footprint by Up to 65%

Security and observability teams now benefit from reduced storage expenses and longer log retention to support their threat hunting, incident response, and compliance requirements

SAN FRANCISCO–(BUSINESS WIRE)–Elastic (NYSE: ESTC), the Search AI Company, announced the general availability of Elasticsearch logsdb index mode. This latest innovation in log management reduces the storage footprint of log data by up to 65% compared to recent versions of Elasticsearch without logsdb index mode. Now, security and observability teams have increased visibility while keeping all data immediately accessible for analysis.

“Logs are critical for detection and remediation, but the growing log volume generated by infrastructure and applications is driving up costs and forcing compromises that hinder analysis,” said Ken Exner, chief product officer at Elastic. “Logsdb index mode reduces the disk footprint and overall cost of storing log data with features including smart index sorting, synthetic source and advanced compression.”

Logsdb index mode optimizes data ordering, eliminates duplication by reconstructing non-stored field values with synthetic _source, and improves compression with advanced algorithms and codecs. Key benefits include:

• Reduced costs: enables organizations to reduce storage expenses while retaining more data, saving costs across all storage tiers.
• Preservation of valuable data: retains all log data using features like synthetic _source, improving operational efficiency without relying on extra tools or filters.
• Expanded visibility: provides access to all data on one platform without separate silos for various data, accelerating problem resolution, investigation, and remediation for site reliability engineers (SREs) and security operations center (SOC) teams.
• Streamlined access to data: retains actionable data efficiently, enabling troubleshooting, trending and analysis for SRE teams, and allows SOC teams to swiftly search all of their data for investigation and threat hunting.

Availability

Logsdb index mode is generally available for Cloud Hosted and Self-Managed customers starting in version 8.17 and is enabled by default for logs in Elastic Cloud Serverless.

Basic logsdb index mode capabilities are available to organizations with Standard, Gold, and Platinum licenses. Complete logsdb index mode capabilities are available to Serverless customers as well as organizations with an Enterprise license.

Read the blog to learn how to get started, or start your free trial now.

About Elastic

Elastic (NYSE: ESTC), the Search AI Company, enables everyone to find the answers they need in real-time using all their data, at scale. Elastic’s solutions for search, observability, and security are built on the Elastic Search AI Platform, the development platform used by thousands of companies, including more than 50% of the Fortune 500. Learn more at elastic.co.

Elastic and associated marks are trademarks or registered trademarks of Elastic N.V. and its subsidiaries. All other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241213828255/en/

Media Contact

Elastic PR

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Technology Software Networks Artificial Intelligence Internet

MEDIA:

Logo

Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for December 2024 and Availability of 19(a) Notice

NEW YORK–(BUSINESS WIRE)–
NYLI CBRE Global Infrastructure Megatrends Term Fund (the “Fund”) (NYSE: MEGI) today announced the Fund’s monthly distributions for December 2024 of $0.1250 per common share. The Fund’s current annualized distribution rate is 11.30% based upon the closing price of $13.28 on December 11, 2024, and 10.16% based upon the Fund’s closing NAV of $14.77 as of the same date.

Dividend Distribution Schedule:

	Ex-Dividend Date	Record Date	Payable Date
December	12-23-2024	12-23-2024	12-31-2024

The amounts and sources of distributions reported in this Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s Distribution Policy.

Future earnings of the Fund cannot be guaranteed, and the Fund’s distribution policy is subject to change. For more information on the Fund, please visit the Fund’s website here.

The Fund’s monthly distribution is set by its Board of Trustees. The Board reviews the Fund’s distribution on a quarterly basis in view of its net investment income, realized and unrealized gains, and other net unrealized appreciation or income expected during the remainder of the year. The Fund strives to establish a level monthly distribution that, over the course of the year, will serve to distribute an amount closely approximating the Fund’s net investment income and net realized capital gains during the year.

The following table sets forth the estimated sources of income of the current distribution, and the cumulative distributions paid this fiscal year to date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. All amounts are expressed on a per share of common stock basis and as a percentage of the distribution amount.

Data as of 12/31/2024
Source	Current Distribution per Share	Percent of Current Distribution	Fiscal YTD Cumulative Distribution per Share	Fiscal YTD Percent of Total Cumulative Distributions
Net Investment Income	$0.1001	80%	$0.6015	69%
Net Realized Short-Term Capital Gains	$0.0249	20%	$0.1972	22%
Net Realized Long-Term Capital Gains	$0.0000	0%	$0.0763	9%
Return of Capital or Other Capital Sources	$0.0000	0%	$0.0000	0%
Total per Share	$0.1250	100%	$0.8750	100%
Fund Performance and Distribution Rate Information as of 11/30/2024
Average annual total return1 (in relation to the net asset value (NAV))				– 0.75%
Annualized current distribution rate expressed as a percentage of month end NAV as of 11/30/2024				9.87%2
Cumulative total return3 (in relation to NAV (not annualized)) for the fiscal period ending 11/30/2024				6.66%
Cumulative fiscal year distribution rate as a percentage of NAV as of 11/30/2024				4.94%4

				1.		Represents the annualized total return in relation to the change in NAV from inception (10/27/2021) through 11/30/2024.
				2.		Represents the current monthly distribution rate annualized as a percentage of NAV as of 11/30/2024.
				3.		Represents the cumulative total return in relation to the change in NAV for the current fiscal period 6/1/2024 through 11/30/2024.
				4.		Represents the cumulative distribution rate for the current fiscal period 6/1/2024 through 11/30/2024, which is determined by dividing the dollar value of distributions in the period by the NAV as of 11/30/2024.

There is no assurance the Fund will continue to pay regular monthly distributions or that it will do so at a particular rate.

You should not draw any conclusions about the Fund’s investment performance from the amount of its distribution to shareholders.

Any distributions in excess of the Fund’s current and accumulated earnings and profits will be treated first, as a tax-deferred return of capital, which is applied against and will reduce the adjusted tax basis of shares and, after such adjusted basis is reduced to zero, will generally constitute capital gains. A return of capital distribution may lower a shareholder’s basis in the Fund, causing a potential future tax consequence in connection with the sale of Fund shares, even if such shares are sold at a loss to the shareholder’s initial investments.

Any amounts and sources of distributions are only estimated and are not being provided for tax reporting purposes. The actual amounts and sources of income of the amounts for tax reporting purposes will depend on the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV for the calendar year that will advise how to report these distributions for federal income tax purposes.

The Fund is a closed-end fund, which is traded on the New York Stock Exchange and invests primarily in income-producing equity securities issued by infrastructure companies. Holdings are subject to change. Past performance is no guarantee of future results.

The Fund’s daily New York Stock Exchange closing prices, net asset values per share, as well as other information are available by clicking here or by calling the Fund’s shareholder servicing agent at (855) 456-9683.

Before considering an investment in the Fund, you should understand that you could lose money. There are risks inherent in all investments.

For more information about the Fund, including specific risks, please visit our website here.

About New York Life Investments

With over $750 billion in assets under management as of September 30, 2024, New York Life Investments, a Pensions & Investments’ Top 30 Largest Money Manager*, is comprised of the affiliated global asset management businesses of its parent company, New York Life Insurance Company, and offers clients access to specialized, independent investment teams through its family of affiliated boutiques. New York Life Investments remains committed to clients through a combination of the diverse perspectives of its boutiques and a long-lasting focus on sustainable relationships.

*New York Life Investment Management ranked 26^th largest institutional investment manager in Pensions & Investments‘ Largest Money Managers 2024 published June 2024, based on worldwide institutional AUM as of 12/31/23. No direct or indirect compensation was paid for the creation and distribution of this ranking.

About CBRE Investment Management

CBRE Investment Management Listed Real Assets LLC is the listed real assets arm of CBRE Investment Management, a leading global real assets investment management firm with $148.3 billion in assets under management* as of September 30, 2024, operating in more than 30 offices and 20 countries around the world. Through its investor-operator culture, the firm seeks to deliver sustainable investment solutions across real assets categories, geographies, risk profiles and execution formats so that its clients, people and communities thrive.

CBRE Investment Management is an independently operated affiliate of CBRE Group, Inc. (NYSE:CBRE), the world’s largest commercial real estate services and investment firm (based on 2023 revenue). The company has more than 130,000 employees (including Turner & Townsend employees) serving clients in more than 100 countries. CBRE Investment Management harnesses CBRE’s data and market insights, investment sourcing and other resources for the benefit of its clients. For more information, please visit www.cbreim.com.

*Assets under management (AUM) refers to the fair market value of real assets-related investments with respect to which CBRE Investment Management provides, on a global basis, oversight, investment management services and other advice and which generally consist of investments in real assets; equity in funds and joint ventures; securities portfolios; operating companies and real assets-related loans. This AUM is intended principally to reflect the extent of CBRE Investment Management’s presence in the global real assets market, and its calculation of AUM may differ from the calculations of other asset managers and from its calculation of regulatory assets under management for purposes of certain regulatory filings.

This press release is not an offer to sell securities and is not a solicitation of an offer to buy securities, nor will there be any sales of securities in any jurisdiction where the offer or sale is not permitted.

New York Life Investment Management LLC engages the services of SEC-registered advisors. CBRE Investment Management Listed Real Assets (CBRE Investment Management) is unaffiliated with New York Life Investment Management LLC. “New York Life Investments” is both a service mark, and the common trade name, of certain investment advisors affiliated with New York Life Insurance Company. Securities distributed by NYLIFE Distributors LLC, 30 Hudson Street, Jersey City, NJ 07302, Member FINRA/SIPC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241213624539/en/

Media:

New York Life Investments:

Sara Guenoun

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo

Know Labs, Inc. Announces $300K Registered Direct Offering

SEATTLE–(BUSINESS WIRE)–Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a registered direct offering with gross proceeds to the company of  $300K before deducting placement agent fees and other estimated expenses payable by the Company.

This was a unit offering comprised of one share of stock and one warrant. The purchase price of the unit was $0.24 a share and the warrant is exercisable at $0.24. The warrants will expire on the fifth anniversary of the warrant issuance. The warrants also have a cashless exercise option in certain circumstances. This was a registered direct offering priced at-the-market under NYSE American rules.

The offer and sale of the units is being made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-276246) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) on December 22, 2023 and declared effective by the SEC on January 11, 2024, as supplemented by a prospectus supplement dated December 13, 2024 and filed with the SEC pursuant to Rule 424(b) (the “Prospectus Supplement”) under the Securities Act of 1933, as amended (the “Securities Act”). The offering of the units is being made only by means of the Prospectus Supplement that forms a part of the effective Registration Statement. A final Prospectus Supplement and the accompanying base prospectus relating to the units being offered in the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final Prospectus Supplement and the accompanying base prospectus may also be obtained, when available, from Know Labs, Inc. Attn: Secretary at 619 Western Avenue, Suite 610, Seattle, WA 98104, by phone at (206) 903-1351 or e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Further information can be found in Know Labs, Inc.’s Form 8-K filing with the Securities and Exchange Commission expected on or about Monday, December 16, 2024.

For more information on Know Labs, visit www.knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile, bench-top or other form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s technology is applicable to many diverse fields of use. The Company’s first expected application of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241213547929/en/

Know Labs, Inc. Contact:

Email: [email protected]

Ph. (206) 903-1351

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Wearables/Mobile Technology Technology Medical Devices Other Technology Health Technology Other Health Biometrics Biotechnology General Health Health

MEDIA:

Logo

Walgreens Launches Inaugural Patient Advisory Board to Advance Access and Representation in Clinical Research

The Walgreens Patient Advisory Board will collaborate with the Walgreens Clinical Trials team to provide insights aimed at increasing representation in clinical trials.

DEERFIELD, Ill.–(BUSINESS WIRE)–
With a history of more than 120 years serving communities across the country, Walgreens prides itself in being a trusted retail pharmacy partner for more than 9 million patients and customers it serves each day. Walgreens is amplifying its commitment to its patients and partners through the formation of the Walgreens Clinical Trials Patient Advisory Board. Since its launch in June 2022, the Walgreens Clinical Trials team has reached more than 7 million patients to potentially recruit into sponsor-led clinical trials. As the team continues expanding its scope and raising awareness about the importance of community-centered clinical research, the Patient Advisory Board members will offer key patient insights that are an invaluable resource to the delivery and advancement of clinical trials.

The inaugural Patient Advisory Board consists of 10 patient experts who will leverage both lived and learned experiences to inform clinical trial recruitment and retention efforts to increase access and representation in clinical research in communities that have historically been excluded. Ramita Tandon, chief biopharma services officer, is standing up the Board as part of Walgreens’ commitment to bringing community-based clinical research to more people that may benefit from it.

“I am proud to engage with our inaugural cohort of Patient Advisory Board members to increase awareness and representation in clinical trials. Only 5% of the U.S. population participates in clinical trials and nearly 80% of trials fail to meet their enrollment goals, often contributing to delays in bringing new medications to patients,” said Tandon. “Our Patient Advisory Board members will help inform how we approach our sponsor-led clinical trials to better serve our patients and partners.”

With increasing regulatory focus on incorporating patients’ perspectives in medical product development,^1,2 and the growth of precision medicine,³ now more than ever, it’s important to engage with patients and individuals who have had experience with clinical research as their lived experiences offer an opportunity to continue improving clinical trials to best serve patients.

Walgreens Clinical Trials Patient Advisory Board members will commit to serve a 2-year term and will offer ongoing counsel, diverse thinking and expertise to inform Walgreens Clinical Trials efforts.

Learn more about Walgreens Clinical Trials here. ​

About Walgreens ​

Founded in 1901, Walgreens (www.walgreens.com) has a storied heritage of caring for communities for generations, and proudly serves nearly 9 million customers and patients each day across its approximately 8,500 stores throughout the U.S. and Puerto Rico, and leading omni-channel platforms. Walgreens has approximately 220,000 team members, including nearly 90,000 healthcare service providers, and is committed to being the first choice for retail pharmacy and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities.​

Walgreens is the flagship U.S. brand of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. Its retail locations are a critical point of access and convenience in thousands of communities, with Walgreens pharmacists playing a greater role as part of the healthcare system and patients’ care teams than ever before. Walgreens Specialty Pharmacy provides critical care and pharmacy services to millions of patients with rare disease states and complex, chronic conditions.

1. Patient Engagement Collaborative. https://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-collaborative
2. Patient-Focused Drug Development: Workshop to Discuss Methodologic and Other Challenges Related to Patient Experience Data. December 13, 2024 https://www.fda.gov/drugs/news-events-human-drugs/patient-focused-drug-development-workshop-discuss-methodologic-and-other-challenges-related-patient
3. https://www.biospace.com/press-releases/precision-medicine-market-size-to-reach-usd-470-53-billion-by-2034

View source version on businesswire.com: https://www.businesswire.com/news/home/20241213029711/en/

Carmen Lopez

Walgreens Media Relations

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Research Discount/Variety Clinical Trials Convenience Store Biotechnology Health Pharmaceutical Retail Science

MEDIA:

Logo

RLJ Lodging Trust Announces Dividends for Fourth Quarter of 2024

BETHESDA, Md.–(BUSINESS WIRE)–
RLJ Lodging Trust (the “Company”) (NYSE: RLJ) today announced that its Board of Trustees has declared a quarterly cash dividend of $0.15 per common share of beneficial interest. The dividend is payable on January 15, 2025, to shareholders of record as of December 31, 2024.

The Board of Trustees also declared a quarterly cash dividend of $0.4875 on the Company’s Series A Preferred Shares. The dividend is payable on January 31, 2025, to shareholders of record as of December 31, 2024.

About Us

RLJ Lodging Trust is a self-advised, publicly traded real estate investment trust that owns primarily premium-branded, high-margin, focused-service and compact full-service hotels.

Forward Looking Statements

This information contains certain statements, other than purely historical information, including estimates, projections, statements relating to the Company’s business plans, objectives and expected operating results, and the assumptions upon which those statements are based, that are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the use of the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “may,” “will,” “will continue,” “intend,” “should,” “may,” or similar expressions. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, beliefs and expectations, such forward-looking statements are not predictions of future events or guarantees of future performance and our actual results could differ materially from those set forth in the forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on these forward looking statements and urges investors to carefully review the disclosures the Company makes concerning risks and uncertainties in the sections entitled “Risk Factors,” “Forward- Looking Statements,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report, as well as risks, uncertainties and other factors discussed in other documents filed by the Company with the Securities and Exchange Commission.

For additional information or to receive press releases via email, please visit our website: http://www.rljlodgingtrust.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241213212150/en/

Sean M. Mahoney, Executive Vice President and Chief Financial Officer – (301) 280-7774

KEYWORDS: District of Columbia Maryland United States North America

INDUSTRY KEYWORDS: REIT Other Construction & Property Lodging Construction & Property Travel

MEDIA:

Logo